A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 1,769 shares of TBPH stock, worth $15,478. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,769
Previous 1,452 21.83%
Holding current value
$15,478
Previous $12,000 16.67%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$7.66 - $10.25 $2,428 - $3,249
317 Added 21.83%
1,769 $14,000
Q2 2024

Jul 30, 2024

SELL
$8.29 - $9.92 $426,304 - $510,126
-51,424 Reduced 97.25%
1,452 $12,000
Q1 2024

May 01, 2024

BUY
$8.22 - $11.59 $61,723 - $87,029
7,509 Added 16.55%
52,876 $474,000
Q4 2023

Jan 24, 2024

BUY
$8.58 - $11.4 $7,164 - $9,519
835 Added 1.88%
45,367 $509,000
Q3 2023

Oct 26, 2023

BUY
$8.38 - $10.44 $16,701 - $20,806
1,993 Added 4.69%
44,532 $384,000
Q2 2023

Aug 10, 2023

SELL
$10.16 - $11.92 $106,893 - $125,410
-10,521 Reduced 19.83%
42,539 $440,000
Q1 2023

May 04, 2023

BUY
$9.87 - $11.44 $68,586 - $79,496
6,949 Added 15.07%
53,060 $575,000
Q4 2022

Feb 09, 2023

BUY
$9.65 - $11.34 $45,934 - $53,978
4,760 Added 11.51%
46,111 $517,000
Q3 2022

Nov 10, 2022

BUY
$8.39 - $10.22 $55,013 - $67,012
6,557 Added 18.85%
41,351 $419,000
Q2 2022

Jul 26, 2022

BUY
$8.41 - $10.34 $292,617 - $359,769
34,794 New
34,794 $315,000
Q1 2022

May 10, 2022

SELL
$8.33 - $12.96 $83,483 - $129,885
-10,022 Closed
0 $0
Q4 2021

Feb 08, 2022

BUY
$7.42 - $11.05 $74,363 - $110,743
10,022 New
10,022 $110,000

Others Institutions Holding TBPH

About Theravance Biopharma, Inc.


  • Ticker TBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,782,400
  • Market Cap $584M
  • Description
  • Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...
More about TBPH
Track This Portfolio

Track Mirae Asset Global Investments Co., Ltd. Portfolio

Follow Mirae Asset Global Investments Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.